Allogene Therapeutics, Inc. (ALLO)
 NASDAQ: ALLO · Real-Time Price · USD
 1.210
 -0.010 (-0.82%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.220
 +0.010 (0.83%)
  After-hours: Oct 30, 2025, 7:30 PM EDT
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm) 
 $22.00K
Revenue Growth 
 -76.84%
P/S Ratio 
 n/a
Revenue / Employee 
 n/a
Employees 
 229
Market Cap 
268.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% | 
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% | 
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% | 
| Dec 31, 2021 | 114.09M | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
ALLO News
- 15 hours ago - Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 27 days ago - Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript - Seeking Alpha
- 2 months ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - Allogene Therapeutics: Important Catalysts Guided For Early 2026 - Seeking Alpha
- 2 months ago - Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - GlobeNewsWire